Infectious Diseases News and Research

RSS

Oral cancer linked to oral sex: Study

Swedish researchers have found that the Human papillomavirus (HPV) that causes cervical cancer in women is also a risk factor for oropharyngeal squamous cell carcinoma (OSCC) or oral and throat cancer in men even if they do not smoke or consume alcohol.

21 Oct 2010

Zyvox achieves higher clinical success rate than vancomycin in MRSA nosocomial pneumonia study

Results of a new international phase 4 study of patients with nosocomial pneumonia due to proven methicillin-resistant Staphylococcus aureus (MRSA) demonstrated that the antibiotic Zyvox® (linezolid) achieved a statistically significantly higher clinical success rate compared with vancomycin for the primary endpoint. The ZEPHyR (Linezolid in the treatment of subjects with nosocomial pneumonia proven to be due to methicillin-resistant Staphylococcus aureus) study was the largest ever conducted in this population.

21 Oct 2010

PolyMedix plans PMX-60056 Phase 2 clinical trial in interventional cardiology

PolyMedix, Inc., a biotechnology company focused on developing new therapeutic drugs to treat infectious diseases and acute cardiovascular disorders, has announced plans for a Phase 2 clinical trial of PMX-60056 in interventional cardiology, and the establishment of a focused Heptagonist Clinical Advisory Board (CAB). PMX-60056 is a synthetic small-molecule designed to reverse the anticoagulant activity of heparin and low molecular weight heparins (LMWH).

21 Oct 2010

BioCryst to present intravenous peramivir data for influenza treatment at IDSA meeting

BioCryst Pharmaceuticals, Inc. announced the presentation of data related to intravenous (i.v.) peramivir for the treatment of influenza at the 48th Annual Infectious Diseases Society of America (IDSA) meeting being held in Vancouver, Canada.

21 Oct 2010

Researchers investigate reverse zoonosis in marine invertebrate

The spread of lethal diseases from animals to humans has long been an issue of great concern to public health officials. But what about diseases that spread in the other direction, from humans to wildlife. A multidisciplinary team of researchers at the University of Georgia has just been awarded a five-year $2 million Ecology of Infectious Diseases grant from the National Science Foundation and National Institutes of Health to study the first known case of such a "reverse zoonosis" that involves the transmission of a human pathogen to a marine invertebrate, elkhorn coral.

21 Oct 2010

LSUHSC receives NIH grant for research on cancer and infectious diseases

LSU Health Sciences Center New Orleans has been awarded $12 million over five years by the National Institutes of Health to conduct research on diseases like prostate and stomach cancers, lymphoma and leukemia, dengue fever, tuberculosis, and herpes infections, as well as to support the development of academic research scientists.

21 Oct 2010

New immunoSEQ bioinformatics software platform helps monitor adaptive immune system

Adaptive TCR Technologies, a biotech firm based in Seattle, WA, announced today the release of its immunoSEQ profiling service and immunoSEQ Analyzer bioinformatics software platform. Together, these tools provide researchers and clinicians the ability to profile and monitor the adaptive immune system at a level of detail that has never before been possible.

21 Oct 2010

NIH awards $7 million grant to provide sustained care for HIV-positive inmates

The University of Illinois at Chicago has received a $7 million grant from the National Institutes of Health to study effective ways to seek, test, and treat inmates with HIV.

21 Oct 2010

LANL's researcher to implement first human trial of mosaic HIV vaccine candidate

Los Alamos National Laboratory researcher Bette Korber is part of an international team of investigators working to design and implement the first human trial of a mosaic HIV vaccine candidate. The vaccine represents a novel strategy for fighting the virus that causes AIDS by attempting to address one of the most daunting challenges in HIV vaccine design: the virus's extensive genetic diversity.

20 Oct 2010

RWV bioreactor creates 3-D cell culture models

The cells and tissues in our bodies grow, develop and interact in a highly complex, three-dimensional world. Likewise, the various microbial pathogens that invade our bodies and cause infectious disease interact with this complex 3-D tissue milieu. In the current issue of the journal Nature Reviews Microbiology, researcher Cheryl Nickerson and her team at the Biodesign Institute at Arizona State University highlight an innovative approach for studying cells in 3-D.

20 Oct 2010

NIAID announces four new contracts for clinical trials to address problem of antimicrobial resistance

The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, today announced four new contracts for large-scale clinical trials that address the problem of antimicrobial resistance.

20 Oct 2010

U-M hopes to make concept of recycling pacemakers a life-saving reality

Millions worldwide die each year because they can't afford a pacemaker. Meanwhile heart patients in the United States say they'd be willing to donate theirs after death to someone in need.

20 Oct 2010

Opinions: Mdgs in Africa; development maintenance; U.S. efforts to eradicate polio; Global Fund commitment

Addressing the Millennium Development Goals (MDGs) in Africa will not only require extra spending, but also better spending, as well as the improvement of social services and priority setting, Kingsley Alu writes in a Leadership column.

20 Oct 2010

Johnson & Johnson third quarter sales decrease 0.7% to $15.0 billion

Johnson & Johnson today announced sales of $15.0 billion for the third quarter of 2010, a decrease of 0.7% as compared to the third quarter of 2009. Operational results increased 0.1% and the negative impact of currency was 0.8%. Domestic sales declined 2.5%, while international sales increased 1.1%, reflecting operational growth of 2.6% and a negative currency impact of 1.5%.

19 Oct 2010

Cytheris initiates ORVACS Phase II clinical trial to study HIV infection

Cytheris SA, a clinical stage biopharmaceutical company focused on research and development of new therapies for immune modulation, today announced the initiation of Phase II clinical trial of the company's investigative immunomodulatory agent, CYT107 (rhIL-7), in combination with two potent antiretroviral drugs represented by the integrase inhibitor raltegravir (ISENTRESS- Merck & Co.) and the CCR5 inhibitor, maraviroc (SELZENTRY- ViiV Healthcare).

19 Oct 2010

BD, Walter and Eliza Hall Institute collaborate to commercialize antibodies

The Walter and Eliza Hall Institute of Medical Research in Melbourne, Australia, has entered a collaboration with New Jersey based medical technology company BD to evaluate and potentially develop for research and diagnostic use some of the institute's reagents.

19 Oct 2010

New research coalition to design first human trial of mosaic HIV vaccine candidate

Duke University Medical Center vaccine experts have assembled an international team of investigators to design and implement the first human trial of a mosaic HIV vaccine candidate, a novel strategy that attempts to counter one of the most daunting challenges in HIV vaccine design: the virus's extensive genetic diversity

19 Oct 2010

Scientists complete genetic blueprints for 13 different strains of Lyme disease bacteria

Scientists supported by the National Institutes of Health (NIH) have determined the complete genetic blueprints for 13 different strains of Borrelia burgdorferi, the bacteria that cause Lyme disease. The achievement should lead to a better understanding of how genetic variations among strains may result in different courses of illness in people with Lyme disease, the most common tickborne disease in North America. The wealth of new genetic data will also help scientists develop improved ways to diagnose, treat and prevent Lyme disease.

19 Oct 2010

The state of sexually transmissible and blood-borne infections in Australia: the 2010 Surveillance Reports

Australia last year reported its largest number of new HIV cases since the early 1990s but has seen a reduction in cases of hepatitis, infectious syphilis and gonorrhoea, new data contained in HIV, viral hepatitis and sexually transmissible infections in Australia Annual Surveillance Report 2010 shows.

18 Oct 2010

Sequella to develop SQ109 further with EDCTP, LMU, and TB experts in PanACEA

Sequella, Inc., a clinical-stage company focused on commercializing novel drugs for treatment of life-threatening infectious diseases, announced it has signed an agreement with the Ludwig-Maximilians-University (LMU) of Munich to coordinate a European Union grant for Phase 2 clinical trials of SQ109 in adult pulmonary tuberculosis (TB) in seven sites in Africa.

18 Oct 2010

Infectious Diseases News and Research

Oral cancer linked to oral sex: Study

Zyvox achieves higher clinical success rate than vancomycin in MRSA nosocomial pneumonia study

PolyMedix plans PMX-60056 Phase 2 clinical trial in interventional cardiology

BioCryst to present intravenous peramivir data for influenza treatment at IDSA meeting

Researchers investigate reverse zoonosis in marine invertebrate

LSUHSC receives NIH grant for research on cancer and infectious diseases

New immunoSEQ bioinformatics software platform helps monitor adaptive immune system

NIH awards $7 million grant to provide sustained care for HIV-positive inmates

LANL's researcher to implement first human trial of mosaic HIV vaccine candidate

RWV bioreactor creates 3-D cell culture models

NIAID announces four new contracts for clinical trials to address problem of antimicrobial resistance

U-M hopes to make concept of recycling pacemakers a life-saving reality

Opinions: Mdgs in Africa; development maintenance; U.S. efforts to eradicate polio; Global Fund commitment

Johnson & Johnson third quarter sales decrease 0.7% to $15.0 billion

Cytheris initiates ORVACS Phase II clinical trial to study HIV infection

BD, Walter and Eliza Hall Institute collaborate to commercialize antibodies

New research coalition to design first human trial of mosaic HIV vaccine candidate

Scientists complete genetic blueprints for 13 different strains of Lyme disease bacteria

The state of sexually transmissible and blood-borne infections in Australia: the 2010 Surveillance Reports

Sequella to develop SQ109 further with EDCTP, LMU, and TB experts in PanACEA

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News